SLC25A11

Across TCGA pan-cancer cohorts, SLC25A11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC25A11 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SLC25A11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A11 expression acts as an unfavorable survival marker.

ESCA, PRAD, and LUAD are the cancer types where SLC25A11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.095	0.701	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	0.229	0.813	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC25A11–ESCA (OS)

Open the ESCA breakdown →